Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways

BACKGROUND: Factor Xa (FXa) not only plays an active role in the coagulation cascade but also exerts non-hemostatic signaling through the protease-activated receptors (PARs). This study aimed to investigate whether the FXa inhibitor, Rivaroxaban (RIV), attenuates adverse cardiac remodeling in rats w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qian, Zhang, Zhongfan, Chen, Weiwei, Zheng, Haikuo, Si, Daoyuan, Zhang, Wenqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2023
Materias:
Biochemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541813/
https://www.ncbi.nlm.nih.gov/pubmed/37786576
http://dx.doi.org/10.7717/peerj.16097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541813/
https://www.ncbi.nlm.nih.gov/pubmed/37786576
http://dx.doi.org/10.7717/peerj.16097

Ejemplares similares